Top Industry News

A roundup of manufacturing news from Amphastar Pharmaceuticals, Ultragenyx Pharmaceutical, Cellular Origins, Catapult and Resolution Therapeutics. Highlights below.  * Amphastar To Expand US Mfg Capacity  * Ultragenyx Receives FDA Complete Response…

A roundup of bio/pharmaceutical partnering news from AbbVie/IGI Therapeutics and BI/Leo Pharma.  * AbbVie, IGI Therapeutics in $1.9-Bn Trispecific Antibody Drug Pact   * BI, Leo Pharma in $105-M Skin Disease…

Merck & Co. has agreed to acquire Verona Pharma, a bio/pharmaceutical company focused on respiratory diseases, for $10 billion.  Through this acquisition, Merck will add Ohtuvayre (ensifentrine), a selective dual…

Sandoz has started construction of a new $440-million biosimilars production center for sterile product manufacturing in Brnik, Slovenia. The project brings the company’s total planned and ongoing investment in Slovenia…

Vetter, a Ravensburg, Germany-headquartered CDMO of aseptic filling and packaging, has broken ground on a new $285-million clinical manufacturing site in Des Plaines, Illinois.   The facility is expected to be…

Hikma Pharmaceuticals USA has announced it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities in Columbus and Cleveland, Ohio, and Cherry Hill and…

Merck KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, a Stamford, Connecticut-based commercial-stage bio/pharmaceutical company focused on severe rare diseases and cancer, for $3.4 billion. The deal was…

The latest from CDMOs, CMOs, and suppliers featuring BASF, BioSpring, Pace Life Sciences, Aenova, Future Pak, Nippon Shokubai, Azelis/Chimica e Farmaceutica, IMCD, and Axplora.   Chemicals/Chemical API Manufacturing * Axplora Announces $41-M…

A roundup of news from AbbVie/Capstan Therapeutics, GSK/Boston Pharmaceuticals and Novo Nordisk. Highlights below.   M&A News * AbbVie To Acquire Capstan Therapeutics for $2.1 Bn * GSK Completes Acquisition of Liver Disease…

Novartis has completed its acquisition of Regulus Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company developing microRNA therapeutics, in a deal worth up to $1.7 billion ($800 million upfront and…